Compare USLM & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USLM | LGND |
|---|---|---|
| Founded | 1948 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | 1994 | N/A |
| Metric | USLM | LGND |
|---|---|---|
| Price | $109.84 | $219.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $138.00 | ★ $256.29 |
| AVG Volume (30 Days) | 119.9K | ★ 192.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 23.22 | N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $144,435,000.00 | N/A |
| Revenue This Year | $27.25 | $1.25 |
| Revenue Next Year | $13.76 | $19.41 |
| P/E Ratio | $103.08 | ★ $76.27 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $94.41 | $98.90 |
| 52 Week High | $141.44 | $247.38 |
| Indicator | USLM | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 48.98 |
| Support Level | $107.82 | $180.85 |
| Resistance Level | $129.37 | $227.92 |
| Average True Range (ATR) | 6.32 | 10.66 |
| MACD | -2.53 | -2.19 |
| Stochastic Oscillator | 19.27 | 42.22 |
United States Lime & Minerals Inc is engaged in the business of manufacturing lime and limestone products including PLS, quicklime, hydrated lime and lime slurry. It supplies its products predominantly to the construction (including highway, road, and building contractors), industrial (including paper and glass manufacturers), environmental (including municipal sanitation and water treatment facilities and flue gas treatment processes), metals (including steel producers), oil and gas services, roof shingle manufacturers and agriculture (including poultry and cattle feed producers) industries. The company operates through its Lime and Limestone Operations segment.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.